extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti
 
 MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+
+The sarcopenic obesity mechanism presents a counter-cost that may offset GLP-1 savings: if 64.8% discontinue within one year and experience preferential fat regain without muscle recovery, the resulting sarcopenic obesity increases fall risk, fractures, and disability costs—particularly in the Medicare population. This suggests the net cost impact may be even more inflationary than projected, or potentially negative for elderly subpopulations where functional decline costs exceed metabolic savings.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
 
 No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+
+The low persistence rate has a compounding negative effect beyond lost metabolic benefits: patients who discontinue after losing 15-40% of weight as lean mass experience preferential fat regain without muscle recovery, creating a worse body composition profile than baseline. This weight cycling mechanism means discontinuation doesn't just reset patients to their starting point—it leaves them with sarcopenic obesity, a higher-risk phenotype than simple obesity.
+
 ---
 
 Relevant Notes:

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
 
 The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+
+The socioeconomic discontinuation gradient creates a health equity concern beyond access: lower-income patients who discontinue due to affordability are more likely to experience the sarcopenic obesity trap (muscle loss + fat regain) and less likely to have access to the mitigation strategies (high protein diet, resistance training programs) that could prevent it. This suggests GLP-1s may widen health disparities through a mechanism more subtle than simple access.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json

@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md

@@ -7,9 +7,13 @@ date: 2025-07-01
 domain: health
 secondary_domains: []
 format: review
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, sarcopenia, muscle-loss, elderly, safety, lean-mass]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -50,3 +54,12 @@ WHY ARCHIVED: Counter-evidence to the GLP-1 benefit thesis — sarcopenia risk m
 EXTRACTION HINT: The intersection of muscle loss + high discontinuation rates is the key risk — evaluate as a challenge to the cost-savings thesis, not just a clinical side effect
 
 flagged_for_astra: ["GLP-1-induced muscle loss in elderly has parallels to spaceflight muscle atrophy — different mechanism but similar functional consequences"]
+
+
+## Key Facts
+- 15-40% of total weight lost on GLP-1s is lean body mass (not fat)
+- Some analyses suggest up to 60% lean mass loss in certain patients
+- Natural aging reduces skeletal muscle mass by 12-16%
+- Sarcopenic obesity prevalence: 10-20% of older adults
+- 64.8% of GLP-1 patients discontinue within 1 year
+- Next-generation GLP-1 compounds aim to improve muscle preservation